| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,574.0 | 1,602.0 |
| Gross profit | 869.0 | 857.0 |
| Profit before tax | 255.0 | 243.0 |
| Net income | 164.0 | 160.0 |
| EPS (diluted, $ a share) | $0.60 | $0.61 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +2.5% |
|---|---|
| Revenue, year on year | -1.7% |
| Gross margin | 55.2% |
10-Q filed with the SEC, NYSE: OGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Organon & Co.: key numbers
- Share price
- $13.90Close, Nov 16
- Market cap
- $3.65B
- Shares outstanding
- 262.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Organon & Co.
All →Organon & M&A Deal with Sun Pharmaceutical Industries Limited
Organon & Co. provided a status update on its pending merger with Sun Pharmaceutical Industries Limited, noting that it has suspended customary earnings calls and press releases due to the transaction. The company furnished supplemental non-GAAP financial metrics for the third quarter of 2026 in lieu of a formal earnings release while the merger remains active.
- Counterparty
- Sun Pharmaceutical Industries Limited